Objective: To investigate the regulating effect of liraglutide therapy on metabolic disorders in patients with newly diagnosed type 2 diabetes complicated with obesity. Methods: A total of 118 patients with newly diagnosed type 2 diabetes complicated with obesity who were treated in the hospital between September 2014 and January 2017 were collected and divided into the control group (n=59) and observation group (n=59) by random number table. Control group received metformin therapy and the observation group received liraglutide therapy. The differences in levels of glucose metabolism indexes, lipid metabolism indexes and inflammatory factors were compared between the two groups before and after 4 months of treatment. Results: Before treatment, the differences in serum levels of glucose metabolism indexes, lipid metabolism indexes and inflammatory factors were not statistically significant between the two groups. after 4 months of treatment, serum FPG, FIN, F-CP, TC, TG, IL- 1β, IL-6, CRP and TNF-α levels of both groups of patients were lower than those before treatment while HDL-C levels were higher than those before treatment, and serum FPG, FIN, F-CP, TC, TG, IL-1β, IL-6, CRP and TNF-α levels of observation group were lower than those of control group while HDL-C level was higher than that of control group. Conclusion: Liraglutide therapy can effectively optimize the glucose lipid metabolism and reduce the microinflammatory response in patients with type 2 diabetes mellitus complicated with obesity.